ストックスクリーナーアプリを入手
1.94
0.51%
-0.01
前日終値:
$1.95
開ける：
$1.93
24時間の取引高:
5,895
Relative Volume:
0.03
時価総額：
$178.84M
収益：
$47.04M
当期純損益:
$-63.98M
株価収益率:
-2.4058
EPS:
-0.8064
ネットキャッシュフロー:
$-34.39M
1週間 パフォーマンス:
+7.18%
1か月 パフォーマンス:
-1.52%
6か月 パフォーマンス:
-11.42%
1年 パフォーマンス:
+25.97%
1日の値動き範囲:
$1.93
$1.945
1週間の範囲:
$1.81
$1.98
52週間の値動き範囲:
$1.41
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
IPHA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.94 | 179.75M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.46 | 110.02B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
765.12 | 82.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.53 | 59.61B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
890.30 | 56.15B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.51 | 44.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-18 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-09-18 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-07-28 | 開始されました | BTIG Research | Buy |
| 2021-09-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | 開始されました | Goldman | Neutral |
すべてを表示
Innate Pharma Adr (IPHA) 最新ニュース
Earnings call transcript: Innate Pharma Q3 2025 shows innovation progress - Investing.com
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances - Investing.com India
Innate Pharma Q3 2025 slides: Lacutamab progress highlighted amid clinical advances By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma Q3 2025 shows innovation progress By Investing.com - Investing.com UK
Disney, Brookfield, Nu Holdings and more set to report earnings Thursday - Investing.com UK
Pre Market Movers: SLRX, SI, ELDN Swing Big - RTTNews
Innate Pharma stock soars after FDA clears path for Phase 3 trial - Investing.com
Innate Pharma (IPHA) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? - MSN
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer - GlobeNewswire Inc.
Innate Pharma FY2025 EPS Forecast Increased by HC Wainwright - MarketBeat
Innate Pharma (NASDAQ:IPHA) Stock Price Down 3.9%Time to Sell? - MarketBeat
Lucid Capital Markets initiates coverage on Innate Pharma stock with Buy rating - Investing.com India
Goldman Sachs Sticks to Their Hold Rating for Innate Pharma SA (IPHYF) - Barchart.com
Leerink Partnrs Forecasts Innate Pharma Q3 Earnings - Defense World
Innate Pharma FY2025 EPS Estimate Increased by HC Wainwright - MarketBeat
Innate Pharma (NASDAQ:IPHA) Downgraded by HC Wainwright to “Neutral” - Defense World
Innate Pharma (NASDAQ:IPHA) Given “Market Perform” Rating at Leerink Partners - Defense World
Leerink Partners downgrades Innate Pharma stock on shift to ADC strategy - Investing.com
Innate Pharma SA Reports First Half 2025 Financial Results - TipRanks
Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway By Investing.com - Investing.com South Africa
Earnings call transcript: Innate Pharma’s Q2 2025 focus on strategic assets - Investing.com
Innate Pharma H1 2025 slides: strategic refocus on key assets extends cash runway - Investing.com
Innate Pharma Reports First Half 2025 Business Update and Financial Results - Placera.se
Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) Short Interest Down 25.8% in August - MarketBeat
Innate Pharma (NASDAQ:IPHA) Trading 1.7% HigherWhat's Next? - MarketBeat
Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – Here’s What Happened - Defense World
Arm Holdings PLC Releases Q2 2025 Financial Report Amid Market Challenges - The Globe and Mail
How strong is Innate Pharma S.A. Depositary Receipt company’s balance sheetSuperior risk-adjusted returns - Jammu Links News
Innate Pharma stock initiated with Buy rating at BTIG on cancer therapy potential - Investing.com
Innate Pharma (NASDAQ:IPHA) Trading 1.7% Higher – What’s Next? - Defense World
Exchange Traded Concepts LLC Has $112,000 Stock Position in Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) - Defense World
Why Kingsoft Cloud Holdings Stock Plummeted by Nearly 8% Today - The Globe and Mail
Should You Buy, Hold, or Sell PDD Holdings Stock Before Q1 Earnings? - The Globe and Mail
Innate Pharma Q1 2025 slides: pipeline advances and Sanofi partnership strengthen outlook - Investing.com
Innate Pharma reports promising preclinical results for cancer drug IPH4502 - Investing.com
What Are Earnings Reports? - MarketBeat
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
AZN Stock Price and Chart — NASDAQ:AZN - TradingView
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - TradingView
Innate Pharma Announces Its Participation in Upcoming Investor Conference By Investing.com - Investing.com India
symbol__ Stock Quote Price and Forecast - CNN
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study - Nasdaq
What is the current Price Target and Forecast for Innate Pharma (IPHA) - Zacks Investment Research
Innate, Sanofi ink licensing deal for NK cells - MarketWatch
Senti Biosciences (SNTI) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
Innate Pharma: AstraZeneca To Discontinue INTERLINK-1 Monalizumab Combination Trial - Nasdaq
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities.com
Annovis Bio (ANVS) Short Interest Ratio and Volume 2025 - MarketBeat
ICE Announces Annual Reconstitution Changes in the ICE Biotechnology Index - FinancialContent
Mersana Therapeutics (MRSN) Short Interest & Short Float | Updated Nov 2025 - MarketBeat
MariMed (MRMD) Short Interest Ratio and Volume 2025 - MarketBeat
Innate Pharma Adr (IPHA) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
大文字化:
|
ボリューム (24 時間):